PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.34%
EBIT growth 1.25-1.5x TRVN's 26.10%. Bruce Berkowitz would verify if strategic initiatives are driving this edge.
30.35%
Operating income growth 1.25-1.5x TRVN's 26.10%. Bruce Berkowitz would see if strategic measures (e.g., cost cutting, product mix) are succeeding.
30.26%
Net income growth 1.25-1.5x TRVN's 24.76%. Bruce Berkowitz would see if strategic cost cutting or product mix explains this difference.
30.58%
EPS growth 1.25-1.5x TRVN's 24.68%. Bruce Berkowitz would check if strategic initiatives like cost cutting or better capital management explain the difference.
33.88%
Diluted EPS growth 1.25-1.5x TRVN's 27.71%. Bruce Berkowitz would verify if strategic moves (e.g., targeted acquisitions, cost cuts) explain the edge.
0.94%
Share count expansion well above TRVN's 0.24%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
5.92%
Diluted share count expanding well above TRVN's 4.06%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
10.50%
Positive OCF growth while TRVN is negative. John Neff would see this as a clear operational advantage vs. the competitor.
10.43%
Positive FCF growth while TRVN is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10668.67%
Negative 10Y OCF/share CAGR while TRVN stands at 69.66%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
79.98%
5Y OCF/share CAGR is similar to TRVN's 77.94%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
60.25%
3Y OCF/share CAGR at 50-75% of TRVN's 85.74%. Martin Whitman would suspect weaker recent execution or product competitiveness.
-3178.86%
Negative 10Y net income/share CAGR while TRVN is at 69.30%. Joel Greenblatt sees a major red flag in long-term profit erosion.
82.89%
5Y net income/share CAGR similar to TRVN's 79.50%. Walter Schloss might see both on parallel mid-term trajectories.
76.87%
3Y net income/share CAGR 75-90% of TRVN's 89.64%. Bill Ackman might push for an operational plan to match or beat the competitor’s short-term growth.
496.60%
Below 50% of TRVN's 11484.61%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
159.22%
Positive 5Y equity/share CAGR while TRVN is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
-89.45%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.48%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-43.72%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
14.13%
We have some new debt while TRVN reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
-30.15%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-30.87%
We cut SG&A while TRVN invests at 13.71%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.